Figure 4.
Protection assay in AGMs
(A) Survival curve. Nine AGMs were immunized twice with CD40.NiV and challenged with 102 PFUs of NiV-B (intratracheal route) (red line). Eight naive animals were used as controls (black dotted line). Gehan-Breslow-Wilcoxon test, ∗∗∗p < 0.001.
(B) Clinical scores and temperatures of naive (black) and vaccinated AGMs (red). Gray dashed line score threshold for ethical considerations (left); median temperature at day 0 (right).
(C) Hematoxylin and eosin staining of collected tissues from the spleen, lungs, and brain (frontal cortex) at necropsy. Representative staining of naive AGMs is shown in (a) and (b) (follicular degeneration and depletion in spleen) and (d) and (e) (interstitial pneumonia with alveolar edema and syncytial formation in the lungs) and of vaccinated AGMs in (c) (follicular hyperplasia in the spleen) and (f) (normal lung tissue). No obvious changes were observed in the brain (frontal cortex).